---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-055935"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:36:11.912774+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics raises $350M in oversubscribed private placement of 8.33M shares at $42/sh

## Summary
- Private placement of 8,333,334 common shares at $42.00/share raises ~$350M gross proceeds.
- Oversubscribed placement includes new and existing investors like Adage Capital, Driehaus, EcoR1, Janus Henderson.
- Net proceeds to fund R&D of clinical-stage candidates, working capital, and general corporate purposes.
- Closing expected March 1, 2024; resale registration statement to be filed within 40 days.

## SEC filing metadata
- accession: 0001193125-24-055935
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312524055935/0001193125-24-055935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312524055935/d773342d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-055935
- JSON: https://secwatch.observer/filing/0001193125-24-055935.json
- Plain text: https://secwatch.observer/filing/0001193125-24-055935.txt

## Key facts
- Material Agreements
  Crinetics Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors named therein valued at aggregate gross proceeds from the Private Placement of approximately $350 million (effective 2024-02-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional accredited investors named therein
  - Value: aggregate gross proceeds from the Private Placement of approximately $350 million
  - Effective: 2024-02-27
  source text: On February 27, 2024, Crinetics Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of 8,333,334 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $ 42.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000119312524055935/0001193125-24-055935-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.